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Summary.-A human tumour which grows as a xenograft in immune-suppressed
mice and forms colonies in vitro has been used to test the correlation between 2
methods of exposure of human tumour cells to chemotherapeutic agents. In vivo
exposure to drugs was achieved by injection of tumour-bearing mice with each of 8
cytotoxic agents. For the in vitro exposure, cell suspensions were incubated for 1 h
with the same series of drugs. The survival of tumour clonogenic cells was assayed
in vitro after either treatment or dose-response curves were obtained. The 8 drugs
were ranked according to their in vivo effect at doses equitoxic to mice, and according
to their in vitro effect at concentrations designed to approximate to levels of drugs in
human plasma. The ranks for in vivo and in vitro exposure correlated well.
IT IS COMMON clinical experience that
tumours of similar histology and stage
show wide differences in response to cyto-
toxic drugs. This may be reflected clinic-
ally as differences in tumour-volume
regression or, less commonly, as a differ-
ence between curative and non-curative
therapy. Whilst factors such as drug dis-
tribution and metabolism, metastatic site
and tumour volume may in part explain
this variability, evidence from the experi-
mental therapy of human tumour xeno-
grafts (Houghton et al., 1977; Nowak et al.,
1978) supports the view that clinical
differences in response reflect differences
in intrinsic cellular chemosensitivity.
Since current methods of clinical drug
evaluation are protracted and relatively
imprecise, a predictive test of chemo-
sensitivity would be advantageous for
selecting active drugs from a range of
currently used agents, and for testing new
compounds. Previous attempts at in vitro
tests for chemosensitivity oftumours have
not met with great success (Mitchell et
al., 1972; Berry et al., 1975) but methods
which measuire depression of colony-
forming ability of the tumour cells appear
more promising (Salmon et al., 1978). It is
essential that the results of in vitro
sensitivity tests satisfactorily reflect the
tumour-cell kill that can be achieved in
vrio. The present study is an attempt to
validate an in vitro chemosensitivity test
using a xenografted human tumour for
which in vrio responses to drugs can be
measured accurately in mice.
MATERIALS AND METHODS
The tumour used in this study was a
poorly differentiated carcinoma of human
pancreas (HX32, Courtenay & Mills, 1978)
transplanted and passaged in the leg muscle
of CBA/lac mice immune-suppressed by the
method of Steel et al. (1978). In brief, mice
were thvmectomized at 4 weeks of age, and
injected 2 weeks later with 200 mg/kg
arabinosyl cytosine (Ara-C) i.p. 2 days before
900rad whole-body 60Co irradiation.
In vivo chemotherapy.-Tumours were
treated by i.p. injection of the host mouse
with graded doses of chemotherapeutic
drugs. Melphalan, adriamycin, cis-platinum
(11) diammine dichloride (cis-Pt(I1)) andA. E. BATEMAN, M. J. PECKHAM AND G. G. STEEL
methotrexate were supplied by the Division
of Cancer Treatment of the U.S. National
Institutes of Health. Chlorambucil and hexa-
methylmelamine (HMM) were gifts from
Professor Ross of the Institute of Cancer
Research, and vinblastine sulphate (Velbe,
Lilly and Co.) and thio-TEPA (Lederle Ltd)
were also used. All drugs except chlor-
ambucil and HMM were injected in saline.
Melphalan was initially dissolved in 01M
HC1 and methotrexate in 2% NaHCO3.
Chlorambucil was dissolved in 2% HCl:98%
ethanol and diluted with 4-5 volumes
propane-1,2-diol and 4-5 volumes saline, and
powdered H1MM was homogenized in di-
methyl-sulphoxide before addition of 9
volumes 5% Tween 80 in saline and re-
homogenization.
Mice were treated when the diameter ofthe
tumour-bearing leg was 8 mm. They were
killed 20 h after drug injection and the
tumour was chopped, incubated in 2 mg/ml
collagenase (Type 1, Sigma) in Ham's
medium for 30 min at 37°C followed by
incubation in0.05% Bactotrypsin in calcium-
and magnesium-free saline for 5 min. The
resulting cell suspension was poured through
a sterile polyester mesh of pore size 25 ,um
and mixed with calf serum (10% of total
volume). The refractile tumour cells were
counted on a haemacytometer. Appropriate
cell dilutions were made and cells were
plated in 0.3% agar medium containing rat
erythrocytes and 20% Special Bobby Calf
Serum (SBCS, Gibco-Biocult) in Ham's F12
medium as described by Courtenay and Mills
(1978). One-ml agar cultures, containing
either 300 control cells or up to 3 x 104
treated cells were gassed with a 5% 02, 5%
C02, 90% N2 mixture and fed after 1 and 2
weeks with 1-5 ml fresh medium. Cell
colonies were scored after 3 weeks. The
plating efficiency (PE) of the untreated
tumour cells was -' 30%. The ratio ofPE of
treated cells to PE of control cells was used
to calculate the fraction of clonogenic cells
surviving treatment. Control PE was deter-
mined in each experiment by plating cells
from each of at least 2 untreated mice; 2 or 3
mice were given each test treatment, and the
surviving fraction of tumour clonogenic cells
was determined for each individual mouse.
In vitro chemotherapy.-Cell suspensions
were prepared as above and aliquots of 106
cells in 1 ml Ham's medium plus 20% SBCS
with various drug concentrations were set up
without delay. These cultures were gassed
with 5% 02, 5% CO2 and 90% N2 before
incubation at 37°C for 1 h followed by 2
washes in phosphate-buffered saline at 5°C
and centrifugation at 600 g. Cells were re-
suspended in 1 ml Ham's medium plus
SBCS, aliquots were counted on a haema-
cytometer, and cells diluted and plated as
above. In all assays heavily irradiated cells
(given 10,000 rad) were added to give a total
cell concentration of 104/ml, to act as "feeder
cells".
All liquids that had come into contact with
the human tumour material were autoclaved
before disposal; all plastics and glassware
were either incinerated or immersed in hypo-
chlorite solution before re-use.
Assessment of the in vitro cytotoxic
activity of the 8 agents was made at drug
concentrations selected on the basis of avail-
able information on human pharmacology.
Human plasma concentrations at different
times after conventional therapeutic doses of
drug were obtained from the literature and
replotted on a linear scale. The integral over
the first hour after administration of the
drug, and the integral of the whole plasma
clearance curve were measured graphically.
For HMM the lh peak value was the
integral between 1.5 and 2-5 h after oral
administration ofthedrug, asthepeakplasma
level occurred at 2 h (Bryan et al., 1968). For
adriamycin the sum ofunchanged adriamycin
and adriamycinol levels was used because,
among the many metabolites, only adriamy-
cinol is known to be cytotoxic (Benjamin et
al., 1977). The drugs used vary in their
stability in in vitro systems. Melphalan,
chlorambucil and thio-TEPA are the least
stable and may have undergone some
hydrolysis during the lh incubation. The
decision to use a lh incubation for all the
drugs was arbitrary. We recognize that the
valid assessment of some drugs may require
a longer or shorter time, and this will be the
subject ofsubsequent research.
RESULTS
The clonogenic cell assay was used to
measure cell survival after the HX32
tumours were exposed by injecting host
mice with each cytotoxic agent. Fig. 1
shows the sensitivity of cells in this
tumour, measured 20 h after a single
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TABLE I.-Ranking of chemotherapeutic
agents for cytotoxic effect in vivo against
clonogenic cells of a human tumour
xenograft (HX32)
LD1o
(mg/kg
Drug in mice)
Melphalan 14-0
HMM
cis-Pt(II)
Surviving fraction
at LD1o
(from Fig. 1)
p
0 004
350 (0O009
13-5 0-024
thio-TEPA 17-0 0-038
Chlorambucil
Methotrexate
Dose (fraction of LDIO)
FIG. 1. Sensitivity of HX32 tumour cells to
drug exposure in mice. Surviving fraction is
plotted against drug dose as a fraction of
LD1o. *=melphalan, O=HMM, 0=cis-
Pt(HI), V =thio-TEPA, V =chlorambucil,
x =methotrexate, A=vinblastine, A=
adriamycin. S.e. of SF at the LD10 dose are
shown.
injection of each drug (tumours were left
in situ for 20 h to allow completion ofdrug
metabolism and to allow for any in vivo
repair of drug damage). Drug dose has
been expressed as a fraction of the LD10,
which is defined as the single i.p. dose of
each agent which kills 10% of mice within
30 days of injection. The LD10 data were
obtained from the literature and from
tests in CBA/lac mice exposed 2-3 weeks
after 900 rad immunosuppressive treat-
ment. The assumption has been made that
LD10 doses, which are by definition
equitoxic to mice, are in proportion to the
maximum tolerated doses in man. There
is a basis for this assumption in reports
comparing drug doses in small-animal
lethality studies with maximum tolerated
doses in human beings (Freireich et al.,
1966; Mellett, 1974; Goldsmith et al.,
1975).
Table I summarizes the in vivo data.
Column 2 gives the LD10 values used and
16-5
200
0-044
0-558
Vinblastine 3 0 0-670
<0-01
<0-001
<0-01
NS
<0-001
NS
<0*05
Adriamycin 9-0 1L10
Cyto-
toxic
drug
rank
in vivo
1
2
3
4-5
4-5
6-5
6-5
8
Column 3 gives the surviving fraction of
tumour cells at that dose. This fraction
was read for each drug at the intersection
of the dose-response curve with the
vertical dotted line drawn at 1-0 on the
abscissa. Fig. 1 shows the standard
error of these values, as calculated
from the regression analysis used to draw
the curves, and the t test was used for
differences between pairs of drugs. The
resulting probabilities are shown in Table
I and drugs are ranked accordingly.
Column 4 gives the rank of each agent in
order ofdecreasing cytotoxicity as used in
the mouse.
In vitro cell survival
Figs. 2, 3 and 4 show the survival of
clonogenic tumour cells exposed in vitro
for 1 h to the 8 cytotoxic drugs. Data
points shown are from at least 2 experi-
ments for each drug. The concave form of
the curves has been noted in other studies
in vitro (e.g. Barranco et al., 1978). The in
vivo and in vitro dose-response curves for
HMM in Figs. 1 and 3 are qualitatively
different. The in vitro data show a plateau-
type response, with little reduction in
a)
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c
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FIGS. 2, 3 and 4. Sensitivity of HX32
tumour cells to drug exposure in vitro.
Data points from at least 2 experiments
are shown. < indicates survivals at the
human plasma concentration over the
peak hour (Level A from Table II).
< indicates survival at human plasma
concentration over the total time measured
(Level B from Table II). (Symbols as in
Fig. 1.)
c c
0
-t
C
0.
surviving fraction between 1 and 10 ,ug/ml,
whereas the in vivo data are fitted by an
exponential curve for doses above 0-5x
LD1o. Rutty & Connors (1977) obtained
low cytotoxicity of HMM in vitro in the
absence of liver microsomes, and con-
cluded that this drug owes its cytotoxicity
II
c
0
0)
Drug concentration (pg/mi)
FIG. 2.-Sensitivity of HX32 tumour cells to
chlorambucil, cis-Pt(TI) and vinblastine in
vitro. (Symbols as in Fig. 1.)
c
0
Li
Oi
CF
0 3
0.1
Drug concentration (pgjml)
FIG. 4.-Sensitivity of HX32 tumour cells to
melphalan and adriamycin in vitro. (Sym-
bols as in Fig. 1.)
0 1 5 10
Drug concentration (pg/mi)
FIG. 3.-Sensitivity of HX32 tumour cells to thio-TEPA, HMM and methotrexate in vitro. (Symbols
as in Fig. 1.)
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(a) On the hypothesis that the initial
1: * . .peak levels ofdrug determine the response,
; _ HMM the average concentration was measured
00 0 .over the first hour after administration (or
the average between 1 5 and 2-5 h after
oral HMM) and these values are quoted as
Level A in Table II. The solid arrows in
Figs. 2-4 show the fraction of cells which
survived incubation with Level A for 1 h.
metabolte (b) On the hypothesis that drug con-
meaol
0 \8 centration x time is the effective para-
meter ofdrug exposure, the integral ofthe
lo- 105 -lo3 whole curve was measured. We then 10-6 10 10 10 estimated the effect of exposing cells for
Molar concentration of drug I h at the concentration (Level B) that
-A comparison of the i vtro action would give the same integral dose (con-
MM with that of its postulated active centration x time). The open arrows in
bolite, pentamethyl monomethylol Figs. 2-4 indicate the fraction of cells
mine. ]Data from 3 experiments, which survive I h incubation in vitro at
Tation in vivo. Ouir method of In Level B. The surviving fractions at the
positions ofthese arrows were used to rank ,posure would, therefore, under- . . i v
e the possible effect of HMM in Table Fori vitr atvity, asdshwnri TbeIII. For 11MM, Levels A and B are at concentrations above I ig/ml. both much higher than the concentration re therefore excluded H1MM from
ithero/inior ecmparison. A saompl at which the plateau level of cell kill was
pitrostulated compactive n.sabolteo reached in vitro and this drug therefore
postulated ab
was omitted from the in vitro ranking. n,-.nt,n.mPfhnxT1 Winnnm11,01-T]"I Mil- 1j1w1V_L V c1 k-Pllailu ny t 11 1 "llul lil luulJylUl 111u1-
amine) was kindly given to us by C. J.
Rutty. This compound showed no plateau
of response (Fig. 5). These results there-
fore support the conclusion that activation
of HMM is needed for maximum cytotoxic
effect.
In this preliminary study we have
assessed the in vitro sensitivity of cells
from HX32 tumour at concentrations
derived by 2 alternative methods from
human plasma clearance curves:
Comparison of in vivo and in vitro
assessments of chemosensitivity
As shown in Table III, there is good
correlation between in vitro ranking based
on plasma concentrations and in vivo
ranking. The ranking at Ih plasma levels
correlates more closely to ranking at
mouse LD10 doses than does the ranking
at the doses equiivalent to the total plasma
clearance curve (Spearman rank correla-
TABLE II. Integrals on drug concentration in hunian plasma (Mg/mi/h)
Dose per
patient
Drulg (mg) A* Bt Reference
Melphalain 30 0 77 1-28 (3) Tattersall et al., 1978
HMMI 12/kg 14 114 (24) Bryan et al., 1968
cis-Pt (II) 20/iM2 1-92 20-2 (20) Malerbi (pers. comm.)
thio-TEPA 0-:3/kg 0-19 0-35 (4) Mellett et al., 1962
Chlorambtucil 10 0-18 0-51 (6) D. Newell (pers. comm.)
Methotrexate 200 107 318 (20) Calvert et al., 1978
Vinblastine 12-16 0-136 0-32 (4) Owellen et al., 1977
Adriamycini 60/Mi2 0(3 1-65 (48) Benjamin et 01., 1977
* Integral over the period 0-1 h after administration (1-5-2-5 h for HMM).
t Integral of the whole plasma clearance curve up to the time (in h) shown in briackets.
1 -
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TABLE III.-In vitro cytotoxicity of 8 drugs against HX32 cells
Surviving Surviving
fraction at fraction at
level A* level B*
(solid Rank (open Rank In vivo
Drug arrows) (A) arrows) (B) rankt
Melphalan 0-17 1 0-041 2 1
cis-Pt (II) 0-29 2 0-012 1 2
Thio-TEPA 0-35 3 0-29 4 3-5
Chlorambucil 0-42 4 0-16 3 3-5
Adriamycin 0-88 5 0 54 5 7
Methotrexate 0-93 6 0-88 6 5-5
Vinblastine 1.0 7 1.0 7 5-5
* From Table II.
t From Table I, omitting HMM.
tion coefficients are 05873 and 05836
respectively). This difference is due to the
reversal of the ranks of melphalan and
cis-Pt(II). The long-term cis-Pt(11) esti-
mate may be too high, as the Pt ion itself
was measured (using the method of
Malerbi & Abel, 1977) in the plasma up
to 20 h after injection, whereas intact
molecules of cis-Pt may no longer be
present. The major discrepancy in ranking
was adriamycin (ranked 5 in vitro but
killing no cells in vivo).
DISCUSSION
The good correlation that we have
found between in vitro and in vivo effects
of drugs lends support to our original
hypothesis. We had proposed that pre-
dictions of the relative efficacy of drugs
against tumour cells in patients might be
made:
(a) by assessing cytotoxicity against
human tumour cells grown in im-
mune-suppressed mice at doses of
drug equitoxic to mice, and
(b) by assessing cytotoxicity to human
tumour cells in vitro at drug con-
centrations found in patients.
Although at the present time there are
unavoidable uncertainties in the transla-
tion of drug levels from in vivo to in vitro,
and from man to mouse, this study has
shown that plausible assumptions lead to
a good correlation between responses seen
in vitro and in the mouse. However, it was
found to be impossible to assess HMM by
an in vitro method because of its require-
ments for in vivo activation, and adriamy-
cin, a drug with a wide spectrum of
clinical activity, failed to show in vivo cell
kill to the extent that would have been
predicted by our in vitro studies. Other
investigators have found adriamycin to
be ineffective against mouse tumours, and
this has been attributed to poor drug
access (Sutherland et al., 1979).
The validity ofthe rankings obtained in
this study depends on the errors involved
in assessing cell survival at a given drug
dose. For HX32 cells the in vivo dose-
response curves for the 8 agents are
exponential in most cases, and values for
surviving fraction (SF) at the LD10 and its
standard error can be calculated from the
regression analysis. This enables the sig-
nificance of differences between cyto-
toxicity of different drugs at the LD10 to
be determined (assuming an accurate
LD10 estimate). The pooling of data from
several mouse strains and several labora-
tories should give a good estimate ofLD1o.
The in vitro dose-response curves are
less well defined than the in vivo curves,
but they are generally not exponential and
have been drawn by eye. Thus the errors
of SF for a given dose are not known
unless experimental observations have by
chance been made at that desired concen-
tration. However, Table III shows that
our assessment of drugs in vitro produces
similar drug rankings, whether the effect
is measured at the peak human plasma
concentration or at the drug level equiva-
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lent to the integral of the whole plasma
clearance curve. Furthermore, both in
vitro rankings correlate well with drug
ranks assessed in vivo.
Salmon et al. (1978), using an alternative
approach for defining in vitro sensitivity
of cells from tumour biopsies, compared
in vitro results with the response of
patients. Their distinction between "re-
sistance" and "sensitivity" in vitro was
somewhat arbitrary, being based on the
integral of a cell-survival vs drug-concen-
tration curve with upper limits of 0a1
Hg/ml for melphalan and bleomycin, and
02 jug/ml for the other drugs used. Avail-
able pharmacological data indicate that
melphalan, for example, gives a peak
plasma level in patients of
- 1 jug/ml
(Tattersall et al., 1978), which is higher
than the maximum concentration used in
vitro by Salmon and his colleagues (1978).
If the 8 drugs of the present study had
been assessed in vitro at a concentration
of 1 Htg/ml, chlorambucil would have been
ranked as the most effective drug followed
by (2) melphalan, (3) thio-TEPA, (4) cis-
Pt(II), (5) adriamycin, (6) methotrexate
and (7) vinblastine. This correlates poorly
with the in vivo ranking (P>0 05 for a
Spearman rank correlation of 0 67). Thus
the use of arbitrary drug concentrations
in vitro precludes any effective ranking of
drugs.
For the 8 drugs in this study, we con-
clude that HMM and adriamycin cannot
be used in vitro to mimic in vivo response.
For the other 6 drugs, lh in vitro exposures
can be used to predict the in vivo effect of
a single injection, ifin vitro concentrations
approximating to drug levels in patients'
plasma are used.
Theoretically, the measurement of drug
cytotoxicity at human plasma concentra-
tions in vitro and at doses equitoxic to
mice in vivo might both be expected to
correlate with cytotoxicity in patients at
drug doses equitoxic to man. The use of
both these methods must be validated by
studies on biopsy material from many
human cancers and correlation of labora-
tory results with patients' responses.
However, we have demonstrated, using
one human tumour xenograft, that the
2 assays correlate well with one another,
and we therefore feel encouraged in our
attempts to use the in vitro test for
alkylating agents and cis-Pt(JJ) to com-
pare the response of tumour biopsy
material with patient response to chemo-
therapy. A study of this type is in pro-
gress, using ovarian carcinoma cells.
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